New guidelines on naming and interchangeability from the Food and Drug Administration point to a changing role for biosimilars, while some of the Trump Administration's policy priorities, if implemented, could alter the dimensions of the American market.
The Atlantic gathered key stakeholders to examine the future for biosimilars domestically and abroad. What impact will the President's policies have on the industry? Will changes in regulation affect how many biosimilars are approved, and what impact will these have on ensuring that these drugs are safe and accessible for the patients who need them?
Watch full session videos
To view photos from this event, please visit our Facebook page
- Wednesday, March 15
- 8:15 a.m.WelcomeMargaret Low, President, AtlanticLIVE
Chester “Chip” Davis, Jr., President and Chief Executive Officer, Association for
- 8:20 a.m.An Update from Capitol HillRepresentative Michael Burgess, MD (R-TX)
With Joie Chen, Journalist and Contributor, AtlanticLIVE
- 8:45 a.m.What the New Rules MeanJim Van Lieshout, Vice President, Market Access and Pharmacy Strategy, Apobiologix
Len Lichtenfeld, MD, Deputy Chief Medical Officer, American Cancer Society
David Fox, Partner, Hogan Lovells
With Joie Chen, AtlanticLIVE
- 9:15 a.m.ClosingMargaret Low, AtlanticLIVE
Also in This Series
The Next Drugs:
An Atlantic Policy Update on Biosimilars
The Atlantic convened key stakeholders to discuss the state of and future for biosimilars.
The Next Drugs:
An Atlantic Policy Briefing on Biosimilars
The Atlantic will gather key stakeholders to examine the emerging world of biosimilars and their regulatory framework in the United States.